On October 2, GRAIL, Inc. rose 6% in regular trading, trading at $139.29 per share, with turnover of $10.37 million. The stock had briefly dipped earlier in the session on short-term profit-taking before staging a swift rebound.

On the news front, the FDA Molecular and Clinical Genetics Devices Advisory Committee recently delivered a strongly favorable vote on GRAIL's Galleri multi-cancer early detection test premarket approval application. The panel voted 10-0 unanimously on safety, 6-4 in favor of efficacy, and 7-2 affirming a positive benefit-risk profile for adults aged 50 and older. Results from the PATHFINDER 2 study showed that adding Galleri to routine screening increased cancer detection 6.5-fold, with 71% of newly identified cancers found at stages I through III. UBS maintained a buy rating, stating the committee's positive vote had nearly eliminated regulatory risk. It is important to note that the advisory committee's recommendation is non-binding, and the final FDA approval decision remains pending.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)